Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA
Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA
Enrolling by invitation · NCT07343661 · Registry updated 2026-01-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA | Eosinophilia, Granuloma, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, Respiratory Hypersensitivity, Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, asthma, autoimmune disease, bronchial disorder, cardiovascular disorder, eosinophilic granulomatosis with polyangiitis, hematologic disorder, hypereosinophilic syndrome, immune system disorder, leukocyte disorder, lung disorder, lymphatic system disorder, lymphoproliferative syndrome, necrotizing vasculitis, obstructive lung disease, pulmonary eosinophilia, respiratory system disorder, skin disorder, skin vascular disease, vascular disorder, vasculitis | Enrolling by invitation | Phase 4 | 2026-01-15 | NCT07343661 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Azienda Ospedaliero Universitaria di Cagliari | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Policlinico Duilio Casula AOU Cagliari | Cagliari | Italy | 1 |